3906 results

Bentley acquired the GoBack catheter

13 Sep 2022

FDA approves US oriented clinical study of Bentley’s BeGraft and Cook’s Zenith® Fenestrated+ Endovascular Graft for treatment of aortic aneurysms CAUTION: Investigational device. Limited by United States law to investigational use.

28 Jun 2023

First Patient Enrolled in SELUTION SLR IDE BTK Study

08 Jun 2022

First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

22 Aug 2022

Vesalio announces FDA Approval of the NeVa VS™ to treat cerebral vasospasm after aneurysmal rupture

15 Sep 2022

Recruitment complete in BEVAR study for on-label use of the Bentley BeGraft peripheral PLUS as a bridging stent

10 Mar 2023

Double barrel in CTO PCI

23 Apr 2024

This EIJ image illustrates a crucial case, emphasizing the importance of confirming wire position in the true lumen during dissection and re-entry techniques in CTO PCI.

Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3

02 Apr 2025

Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.

Author

Kalaivani Mahadevan

Commissural alignment during TAVI

13 Sep 2023

As lifetime management of aortic valve disease patients undergoing TAVI is gaining increased attention, this article sought to summarize the principal idea and possible technical implementation of commissural alignment with current generation transcatheter heart valves (THVs).

Author

Ahmed Abdelhafez

Author

Johannes Wilde

Author

Mohamed Abdel-Wahab

Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)

30 Oct 2024

Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.

Author

Ali Nazmi Calik

3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

22 Mar 2022

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

Author

Ali Nazmi Calik

Biocardia receives FDA breakthrough device designation for CardiAMP Cell Therapy System for heart failure

03 Feb 2022

Pretreatment with heparin in patients with ST-segment elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

01 Sep 2022

Daniele Giacoppo analyses the results of the SCAAR registry which compared patients with STEMI treated by primary PCI in Sweden from January 2008 to December 2016 according to the UFH pretreatment status...

Author

Daniele Giacoppo

MitrAI score: machine learning models to predict mortality at 12, 24, 36 and 48 months in patients with primary and secondary MR treated by TEER

31 Aug 2024

Jonathan Curio provides his take on the MitrAI score study which was presented by Luigi Biasco at ESC Congress 2024 in London.

Author

Jonathan Curio

TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome

03 Sep 2025

Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.

Author

Aaysha Cader

BIOTRONIK's New Absorbable Magnesium Scaffold Achieves Major Milestone in BIOMAG-I Clinical Trial

01 Mar 2022

LimFlow completes enrollment in PROMISE II U.S. Pivotal trial of breakthrough device designed to prevent amputations in no-option patients with chronic limb-threatening ischemia

15 Mar 2022

IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly

28 Jan 2022

Much Awaited, Much Needed: TRANSFORM II Randomized Controlled Trial, by Fondazione RIC, gets rolling

28 Jan 2022

Restriction in supra-annular transcatheter heart valve leaflet mobility during coronary access after valve-in-valve TAVI

05 Apr 2022

This Image in Interventional Cardiology highlights how patient-specific ex vivo simulations offer physicians the opportunity to observe and evaluate the potential in vivo impact of different techniques particularly for complex structural heart interventions.